The abstract is read at the publisher; the summary is JClub's.
A solid-phase synthesis protocol produces tetra-divinylpyrimidine (tetraDVP) cysteine-reactive linkers that rebridge all four interchain disulfide bonds in native IgG1 and IgG4 with one molecule.
- Why it matters: Site-selective antibody bioconjugation needs high precision with fewer off-target effects, but existing routes often require purification or genetic/glycan engineering.
- What they did: The workflow combines solution-phase intermediate synthesis, solid-phase assembly on resin, polyethylene glycol elongation, divinylpyrimidine warhead installation, and mild cleavage to yield a reproducible linker scaffold.
- The result: The method enables rapid, controlled payload installation with a defined payload-to-antibody ratio, avoiding chromatographic purification and genetic/glycan engineering, and can be completed in ~2 weeks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.